Moore Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Moore Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,000	Closed	-$10.4M	–	549
2023 Q3	$10.4M	Buy	+30,000	New	+$10.5M	0.19%	93
2016 Q1	–	Sell	-50,000	Closed	-$6.29M	–	342
2015 Q4	$6.29M	Hold	50,000	–	–	0.2%	132
2015 Q3	$5.21M	Buy	+50,000	New	+$6.42M	0.24%	138

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Moore Capital Management's VRTX Position: Q2 2021 in Review

Moore Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 30,912 shares — an estimated $6.64M sold.

Moore Capital Management first reported a position in VRTX in Q1 2015 and held it in 5 quarters. The position peaked at $12M in Q4 2020. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Moore Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Moore Capital Management sold 30,912 Vertex Pharmaceuticals shares in Q2 2021, an estimated $6.64M.
Moore Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 5 quarters.
Moore Capital Management's Vertex Pharmaceuticals position peaked at $12M in Q4 2020.
976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Moore Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.